

Index

A

- Acute cellular rejection (ACR)
 - diagnostic yield, TBBx, 24
 - LB, 33
 - mononuclear/lymphocytic inflammation, 35
 - perivascular and interstitial mononuclear cell inflammation, 23
 - risk factor, BOS, 104
- Adaptive immunity
 - injury and infections, allograft, 104
 - T and B lymphocytes, 93
- Airway disease, OB
 - pathology, lung transplantation, 85
 - worsening dyspnea, 84
- Airway pathology, lung transplantation
 - ACR and graft atherosclerosis, 23
 - acute and chronic rejection, 21
 - description, 21
 - ISHLT working formulation, 23
 - LB (*see* Lymphocytic bronchiolitis/bronchitis (LBB))
 - OB (*see* Obliterative bronchiolitis (OB))
 - TBBx (*see* Transbronchial lung biopsy (TBBx))
- Alemtuzumab
 - B cells, 268
 - CLL, 267
 - paroxysmal nocturnal hematuria, 268
- Alloantigen, MHC, 93
- Allogeneic T cell responses, human BOS
 - active OB lesion, infiltration, 97
 - alloreactive, 98–99
 - alloreactivity, development of BOS, 98
 - anti-T cell therapies, 101
 - BMT recipients, 97
 - HLA mismatching, 101–102
 - indirect alloantigen recognition, 99
 - phenotypes, 99–101
- Allograft rejection
 - chronic, 51
 - OB, 78–79
- Allograft tolerance, 153
- Alloimmune T cell responses
 - ACR, risk factor of BOS, 104
 - allogeneic (*see* Allogeneic T cell responses, human BOS)
 - alloreactive, antibody response, 103
 - animal models, OB (*see* Obliterative bronchiolitis (OB))
 - CD4-mediated delayed type II hypersensitivity type reaction, 103
 - CD8 T cell cytotoxicity, 102
 - description, 91–92
 - with innate immune responses (*see* Innate immune response)
 - MHC/HLA (*see* Major histocompatibility complex (MHC))
 - solid organ rejection, 92
 - targets of, 103
 - T cells (*see* T cells)
- Alloimmunity, non-BOS
 - antibody-mediated rejection, 54
 - autoimmune T-and B-cell responses, 54
 - CLAD, pulmonary hypertension, 55
 - EMT, 55
 - histopathological process, OB, 54
- Allorecognition
 - animal models, OB, 113
 - direct vs. indirect, heterotopic tracheal transplant model, 109–110
- Antibodies. *See* Antibody-mediated rejection (AMR)

- Antibody-mediated rejection (AMR)
 allograft rejection, 142–143
 BOS, 136
 description, 130
 diagnosis, 139–140
 DSA (*see* Donor-specific antibodies (DSA))
 HLA, 130
 IVIG, 141–142
 LTX, 134–135
 MFI, 139
 plasmapheresis, 141
 recipients, 132
 SOT, 132–134
 stages, 131
- Antigen-presenting cells (APCs)
 macrophages, 157–158
 pDCs, 157
- Antihumoral therapy
 belatacept, 270–271
 bortezomib, 270
 description, 269
 rituximab, 269–270
- APCs. *See* Antigen-presenting cells (APCs)
- Aspiration pneumonia
 and chronic gastroesophageal reflux, 41
 description, 41, 42
 foodstuffs and inorganic crystalline
 “fillers,” 41
 granulomatous inflammation, 43
 morphologic features, 41
- Autoimmunity
 acute rejection pathology, 188
 and allograft dysfunction, 189–190
 BOS, 184
 CD4+ T cells, 187
 and chronic lung diseases, 184–185
 colV, 188
 CXCL8, 188
 IL-17, 189
 lung allograft dysfunction, 191–192
 lung transplant, 184
 Th17 cell biology, 190–191
 tracheal transplantation, 186
- Azathioprine (AZA)
 description, 256
 drug levels, 257
 and MMF, 257–258
 TPMT deficiency, 256
- Azithromycin
 bacterial, 280
 CARV, 280
 cellular mechanisms, 280–281
 chemical structure, 279
 endothelial cells, 282
 immune response, 283
 immunosuppressive protocols, 284
 inflammation, 285–286
 interleukin, 282
 LPS, 282
 LTb4, 283
 LTx, 280
 lung allograft rejection phenotypes,
 286–287
 macrolide resistance, 289
 prophylactic therapy, 288
 treatment, 284–285
- B**
- Bacterial
Clostridium Difficile, 208
 CMV infections, 206
 MRSA, 207
 mycobacterial infections, 207
- BAL. *See* Bronchoalveolar lavage (BAL)
- BALT. *See* Bronchus-associated lymphoid
 tissue (BALT)
- Basiliximab, 265–266
- Belatacept, 270–271
- BMT. *See* Bone marrow transplantation
 (BMT)
- BO. *See* Bronchiolitis obliterans (BO)
- Bone marrow transplantation (BMT), 115
- BOOP. *See* Bronchiolitis obliterans-organizing
 pneumonia (BOOP)
- Bortezomib, 270
- BOS. *See* Bronchiolitis obliterans syndrome
 (BOS)
- Bronchiolitis obliterans (BO)
 animal model, 176–177
 pathogenesis, 177–178
- Bronchiolitis obliterans-organizing pneumonia
 (BOOP)
 etiology, 39
 fibromyxoid plugs, 39, 40
 fusiform proliferations, 39–40
 idiopathic, 39
 inflammatory cells, 40
 OP, acute lung injury, 39
 organizing phase, DAD, 40–41
 rejection biopsies, 39
- Bronchiolitis obliterans syndrome (BOS)
 ACR (*see* Acute cellular rejection (ACR))
 allogeneic T cell responses (*see* Allogeneic
 T cell responses, human BOS)
 allograft dysfunction, 184
 Aspergillus, 160–161
 chronic lung allograft rejection, 278
 diagnosis, 297–298
 ECP, 300–303

- incidence, 261
 - innate immunity, 159–160
 - LTx recipients, 283
 - lung allograft, 160
 - lung histopathology, 184
 - lung transplantation (LTx), 48
 - neutrophilia, 279
 - non-alloimmune mechanisms, 48
 - pathogenesis
 - airway ischemia, 7
 - CARV, 6
 - clinical responses to
 - immunomodulatory therapies, 4
 - CMV disease, 5–6
 - diagnosis and grading, 2, 3
 - GER, 5
 - identification, surrogate markers, 3
 - invasive fungal infections, 6
 - non-BOS acute and/or subacute
 - complications, 3
 - non-CMV β -herpes viruses, 6
 - “non-immune” mechanisms, 4
 - PGD, 5
 - post-transplant bacterial infection, 6
 - post-transplant OB, 2
 - risk factors associated with, 3, 4
 - prevention and treatment, 252
 - risk factors, 184
 - tissue injury and DAMP, 160
 - TLI (*see* Total lymphoid irradiation (TLI))
 - Bronchoalveolar lavage (BAL), 156
 - Bronchus-associated lymphoid tissue (BALT)
 - description, 33, 34
 - large airways, 33
 - and lymphoepithelium from LB, 33
- C**
- Calcineurin inhibitors
 - CsA, 252
 - drug interactions, 254
 - TAC, 254
 - toxicities, 254–255
 - Capillaritis, 140
 - CARVs. *See* Community-acquired respiratory viruses (CARVs)
 - CDC. *See* Complement-dependent cytotoxicity (CDC)
 - CD4-mediated delayed type II hypersensitivity
 - type reaction, 103
 - CD8 T cell cytotoxicity, 102
 - CD4 vs. CD8 T cells, 96
 - Chest radiography
 - imaging, LTx, 60
 - patients and findings, central airway
 - dilation, 60
 - patients with BOS, 61
 - patterns, 60–61
 - respiratory tract infection/graft
 - dysfunction, 60
 - Chronic interstitial fibrosis, 51
 - Chronic lung allograft dysfunction
 - acid and nonacid reflux, 225
 - AMR, 142
 - BAL fluid, 225
 - bile acids, 227
 - biomarkers, 226
 - diagnosis, 140
 - gastric dysmotility, 224–225
 - prevalence and severity, 223
 - and retrograde aspiration, 224
 - Chronic lung allograft dysfunction (CLAD)
 - BAL neutrophilia, 11
 - BOS pathogenesis (*see* Bronchiolitis obliterans syndrome (BOS))
 - chest computerized tomography scans, 52
 - chronic setting, 9
 - common etiologic subtypes, 48, 49
 - and DAD, 10
 - delayed
 - abnormal GER, 7
 - allograft functional, 9
 - emerging phenotypes, 7, 8
 - fundoplication, 9
 - placebo-controlled clinical trial, 7
 - description, 2
 - diagnosis, OB, 79–80
 - diagnostic pathways, 53–54
 - early-onset and late-onset BOS, 11
 - FEV₁, surrogate marker, 2
 - HRCT imaging and lung volume
 - determinations, 11
 - management, BOS, 9, 10
 - and NRAD, 11
 - parenchymal changes, patients, 80
 - parenchymal infiltration, HRCT, 10
 - persistent loss, FEV₁, 2
 - potential etiology
 - chronic allograft rejection subtype, 51
 - graft infection subtype, 50
 - graft infiltration subtype, 50
 - graft vascular obstructive subtype, 50
 - mechanical subtype, 49–50
 - surgical subtype, 49
 - and RAS, 9–10
 - simple lung function, 52
 - subsets, lung transplant recipients, 9
 - syndromes, 11–12

- Chronic lung allograft rejection.
See Azithromycin
- Chronic lung diseases
 COPD, 185–186
 CTD, 184
 IPF, 185
- Chronic obstructive pulmonary disease (COPD), 185–186
- Chronic rejection
 allograft subtype, 51
 APC presence, 106
 lesions, small airways, 22, 23
 lung allograft and alloreactivity, 97
 and OB, 186
 occlusive fibrosis, 92
- Chronic vascular rejection (CVR), 51
- CLAD. *See* Chronic lung allograft dysfunction (CLAD)
- CMV. *See* Cytomegalovirus (CMV)
- Collagen, 175
- Collagen type V (colV), 188
- colV. *See* Collagen type V (colV)
- Community-acquired respiratory viruses (CARVs)
 BAL fluid, 205
 infection, 206
- Comorbid cardiac disease, 86
- Complement-dependent cytotoxicity (CDC), 137
- Computerized tomography (CT)
 air trapping and severity, BOS, 64
 constrictive bronchiolitis, 64
 double-lung transplant and BOS
 man with, 61, 66
 57-year-old man, 61, 64
 59-year-old man, 61, 65
 28-year-old woman, 61, 63
 end-stage constrictive bronchiolitis, 65
 lower lobe bronchial dilation, 65
 middle-aged woman, idiopathic pulmonary fibrosis and left lung transplant, 61, 62
 mosaic perfusion/attenuation, 62
 predictor, BOS, 62–63
 scores and air trapping scores, 66
 serial HRCT scans, 65–66
 transverse and coronal reformatted HRCT images, 61
- Constrictive bronchiolitis
 and acute rejection, 60
 heart–lung transplant, 60
 lung allograft, 60
 transbronchial biopsy and heterogeneous distribution, 59–60
- COPD. *See* Chronic obstructive pulmonary disease (COPD)
- Corticosteroids
 description, 258
 steroid preparations, 258
- CT. *See* Computerized tomography (CT)
- CVR. *See* Chronic vascular rejection (CVR)
- Cyclosporine A (CsA)
 aerosolization, 253–254
 description, 252–253
 efficacy and safety profile, 253
 structure, 253
- Cytokines
 alloreactive CD4 T cells, 102
 CD8 T cell, 96
 IL-2, 94
 primary graft dysfunction, 105
 Th1, 100
 Tregs, 107
- Cytomegalovirus (CMV)
 allograft dysfunction, 200–202
 infection, 203
 mechanisms, 200
 organisms, 203
 pneumonia, 36, 37
 pneumonitis, 5, 202
 prophylactic and preemptive strategies, 5
- D**
- DAD. *See* Diffuse alveolar damage (DAD)
- Damage-associated molecular patterns (DAMPs), 150
- DAMPs. *See* Damage-associated molecular patterns (DAMPs)
- Diagnosis, BOS, 243–244
- Diffuse alveolar damage (DAD)
 lung biopsy specimens, 10
 pleuroparenchymal fibroelastosis, 10
- Diffuse parenchymal lung disease
 amiodarone pulmonary toxicity, 82
 BAL, patients, 82
 chest CT, 81
 COP and AFOP, 81
 description, 80
 drug-induced pneumonitis, 81–82
 early onset and new-onset, DAD, 81
 pulmonary toxicity, 82
 underlying lung disease, 82–84
- Donor-specific antibodies (DSA)
 CDC, 137
 flow cytometry cross-matching, 137–138
 PRA, 138
- DSA. *See* Donor-specific antibodies (DSA)

E

- ECMO. *See* Extracorporeal membrane oxygenation (ECMO)
 ECP. *See* Extracorporeal photopheresis (ECP)
 EMT. *See* Epithelial-to-mesenchymal transition (EMT)
 Epithelial-to-mesenchymal transition (EMT), 55
 Exhaled nitric oxide (eNO), 245
 Extracorporeal membrane oxygenation (ECMO), 306
 Extracorporeal photopheresis (ECP)
 apoptotic cell antigens, 301
 BOS, 301–302
 FEV₁, 303
 solid organ rejection, 301
 T-cell lymphoma, 300
 Extrapolation, 244

F

- FEV₁. *See* Forced expiratory volume in one second (FEV₁)
 Fibrogenesis
 chronic allograft rejection, 170
 lymphocytic infiltration, 170
 mesenchymal cells (*see* Mesenchymal cells)
 myofibroblasts, 170–171
 Fibroproliferation, 287
 Fibrosis
 pathogenesis, 170
 and scarring, airways and blood vessels, 170
 Forced expiratory volume in one second (FEV₁)
 BOS, 304
 defined, 28
 ECP, 303
 Fungal infections, 208

G

- Gastroesophageal reflux (GER)
 acid suppression, 227
 and chronic lung allograft dysfunction, 223–227
 collagen V sensitization and BOS, 5
 diagnosis
 acid reflux, 223
 pharmacologic therapy, 222
 gastric stimulator, 228–229
 laparoscopic nissen fundoplication, 228
 pathophysiology
 GERD, 220
 LES, 220–221

- lung defense mechanisms, 222
 UES, 222
 pharmacologic suppression, gastric acid secretion, 7
 prokinetic drugs, 228
 Pseudomonas colonization, 6
 surgical fundoplication, treatment, 228
 transplant evaluation, 5
 Gastroesophageal reflux disease (GERD), 220, 240–241
 GER. *See* Gastroesophageal reflux (GER)
 Graft *versus* host disease (GVHD), 153
 Gram-negative, 206, 207
 Gram-positive, 207
 GVHD. *See* Graft *versus* host disease (GVHD)

H

- HLA. *See* Human leukocyte antigens (HLA)
 Human leukocyte antigens (HLA), 130
 Hyperpolarized helium (³He), 66

I

- Idiopathic pulmonary fibrosis (IPF), 185
 Immunosuppression, BOS
 calcineurin inhibitors, 252–253
 drugs, 261–264
 induction therapy (*see* Induction therapy)
 lung transplantation, 252
 Induction therapy
 alemtuzumab, 267–268
 anti-CD3 monoclonal antibody, 267
 anti-thymocyte globulin, 265
 clinical trials, 268–269
 drugs, 265, 266
 IL-2 receptor antagonist antibodies, 265
 polyclonal antibodies, 267
 Infections
 antiviral therapy, 210
 bacterial, 206–208
 CARVs, 205–206
 CMV (*see* Cytomegalovirus (CMV))
 fungal, 208
 herpesviruses, 204
 influenza and immunization, 209–210
 Pneumocystis jiroveci, 211–212
 Pseudomonas infection, 211
 Innate immune response
 activation, APC, 105
 APC and T cell alloreactivity, 105–106
 description, 104
 with rejection, 105
 TLRs, 106

- Innate immunity
 and adaptive, 148–149
 APCs, 157–158
 BAL, 156
 BOS, 159–161
 cellular, 149
 effector cells, 158–159
 lung, 148
 protein components, 155
 PRRs, 148
 receptors and ligands
 DAMPs, 150
 MyD88-dependent pathway, 150, 151
 PAMPs, 150
 TLR, 150–151
 solid organ transplantation, 160–161
- International Society for Heart and Lung
 Transplantation (ISHLT), 5
- Intravenous immunoglobulin (IVIG), 141–142
- IPF. *See* Idiopathic pulmonary fibrosis (IPF)
- ISHLT. *See* International Society for Heart
 and Lung Transplantation (ISHLT)
- IVIG. *See* Intravenous immunoglobulin (IVIG)
- L**
- Large airway inflammation. *See* Lymphocytic
 bronchiolitis/bronchitis (LBB)
- LBB. *See* Lymphocytic bronchiolitis/
 bronchitis (LBB)
- LES. *See* Lower esophageal sphincter (LES)
- Leukotriene B4 (LTB4), 283
- Lower esophageal sphincter (LES), 221
- LPA. *See* Lysophosphatidic acid (LPA)
- LTB4. *See* Leukotriene B4 (LTB4)
- LTx. *See* Lung transplantation (LTx)
- Lung allograft rejection, 5
- Lung function
 infant, 244
 tidal breathing, 245
- Lung transplantation (LTx)
 abnormal GER, 5
 AMR, 270
 animal model, 191
 antigen murine orthotopic, 177
 autoimmunity, 188
 benefit, Th2 polarization, 100
 BO, 170
 bortezomib, 269
 BOS, 48, 258
 bronchoscopic transbronchial biopsy, 97
 chronic alloreactivity, 54
 chronic ischemia, 51
 CsA, 254
 description, 252
 drugs, 261–263
 FEV₁, 52
 gastric dysmotility, 224
 GER, 222
 graft dysfunction, 184
 healthy recipients, 48
 immunosuppressive agents, 252
 induction therapy, 265
 lung allograft rejection, 5
 mTOR inhibitor, 260
 non-BOS, 98
 orthotopic mouse model, 111–112
 orthotopic rat model, 113–114
 steroid, 258
 Tregs in, 108
- Lymphocytic bronchiolitis/bronchitis (LBB)
 conducting and respiratory, allografted
 lung, 31
 dense mononuclear cell inflammation, 32
 description, 26
 diagnosis, rejection, 33
 high-grade, 27–28
 ISHLT working formulation, 32
 low-grade, 26, 27
 non-rejection findings (*see* Non-rejection
 findings, LBB)
 polymorphonuclear leukocytes, 28
 potential confounders, 27
 specialized Leu-7 (CD57)-positive T
 lymphocytes, 31–32
 in TBBx, 33
- Lysophosphatidic acid (LPA), 174
- M**
- Macrolide
 allograft insult activates, 278
 azithromycin (*see* Azithromycin)
 chronic lung allograft rejection, 278
 CMV, 278
 IL-17, 279
- Magnetic resonance imaging (MRI)
 hyperpolarized helium (³He), 66
 inhaled gases, 68
 transbronchial biopsy, 68
 42-year-old woman, right lung allograft
 and BOS, 67
- Major histocompatibility complex (MHC)
 alloantigen, 93
 H-2 antigens, 93
 polymorphisms, 92
 structure of, 92, 93
 T cell (*see* T cells)

Mammalian target of rapamycin (mTOR)
 clinical trials, 260–261
 toxicities, 260

Management, pediatric BOS, 245–246

Mean fluorescence intensity (MFI), 139

Mesenchymal cells
 allograft, 172, 173
 epithelial cell injury, 175–176
 LPA, 174
 migration and recruitment, 172, 174
 and myeloid cell interactions, 174–175
 origin, 171
 phenotype, BOS, 174

Mesenchymal stem cell, 172

Methicillin-resistant *Staphylococcus aureus* (MRSA), 207

MFI. *See* Mean fluorescence intensity (MFI)

MHC. *See* Major histocompatibility complex (MHC)

MMF. *See* Mycophenolate mofetil (MMF)

MRI. *See* Magnetic resonance imaging (MRI)

MRSA. *See* Methicillin-resistant *Staphylococcus aureus* (MRSA)

Mycophenolate mofetil (MMF)
 drug levels, 257
 renal and heart transplantation, 257

MyD88. *See* Myeloid differentiation factor 88 (MyD88)

Myeloid differentiation factor 88 (MyD88), 150, 151

Myofibroblast, 170–171

N

Neutrophilic reversible allograft dysfunction (NRAD)
 BAL neutrophilia, 11
 BOS criteria, 11
 emerging phenotypes, CLAD, 8

Nonacid reflux
 acid and, 225
 aspiration, 225

Non-bronchiolitis obliterans syndrome (non-BOS)
 alloimmunity (*see* Alloimmunity, non-BOS)
 CLAD (*see* Chronic lung allograft dysfunction (CLAD))
 healthy LTx recipients, 48
 morbidity and mortality, LTx, 48
 performance, lung allograft, 48

Non-rejection findings, LBB
 aspiration pneumonia, 41–43
 BALT (*see* Bronchus-associated lymphoid tissue (BALT))

BOOP (*see* Bronchiolitis obliterans-organizing pneumonia (BOOP))

CMV pneumonia, 36
 nonspecific chronic bronchiolitis, 34–35
 opportunistic infections, 35–36
Pneumocystis jirovecii pneumonia, 36–38

Nonspecific chronic bronchiolitis
 causes and associations, 35
 defined, 34
 obstructive airways disease, 34

NRAD. *See* Neutrophilic reversible allograft dysfunction (NRAD)

O

OB. *See* Obliterative bronchiolitis (OB)

Obliterative bronchiolitis (OB)
 allograft dysfunction, chronic setting, 9
 AMR, OB/BOS, 30
 autoimmunity (*see* Autoimmunity)
 autopsy material, 29, 30
 biomarkers
 BAL neutrophilia, 77
 diagnosis, BOS, 77
 FeNO, 77–78
 portable NO analyzers, 78
 and BOS, 71–72
 bronchoscopy/surgical lung biopsy (*see* Transbronchial lung biopsy (TBBx))
 capillaritis, 31
 chest imaging
 air trapping, expiratory HRCT, 74–75
 alveolar opacities, 74
 bilateral bronchiectasis, 74, 75
 composite CT scoring systems, 75
 CT findings, 74
 diagnostic evaluation, BOS, 74
 HP³ He MRI, 75–76
 chronic alloreactivity, LTx, 54
 clinical diagnosis, BOS, 2
 clinical presentation and evaluation, 72–73
 collagen fibrosis, 31
 constrictive, 2
 and CVR, 51
 defined, 48
 description, 22
 diagnosis
 allograft rejection, 78–79
 CLAD, 79–80
 confounding conditions, BOS, 78, 79
 diagnosis and grading, BOS, 3
 diffuse parenchymal lung disease, allograft (*see* Diffuse parenchymal lung disease)

- Obliterative bronchiolitis (OB) (*cont.*)
 and EMT, 55
 FEV₁, 28, 72
 hematoxylin and eosin-stained section,
 28, 29
 human-mouse chimera, 115
 infection
 aging, 87
 airway disease, 84–85
 allograft dysfunction, 84
 comorbid cardiac disease, 86
 disorders, ventilation, 85–86
 loss, lung function, 84
 malignancy, 86
 limitations, 87
 linear C4d staining, 31
 location, allorecognition, 113
 lung allograft dysfunction and AMR, 31
 and lymphocytic, 22–23
 management, BOS, 9, 10
 morbidity and mortality, LTx, 71
 mouse BMT, 115
 mucostasis and/or accumulation, foamy, 31
 non-immunologic risk factors, 29
 occurrence of, 22
 original and revised classifications, BOS^a, 72
 orthotopic mouse lung transplant model,
 111–112
 orthotopic rat lung transplant model,
 113–114
 orthotopic tracheal transplant model, 111
 pigs, 114–115
 post-transplant, 2
 rodent heterotopic tracheal transplant
 model, 108–111
 screening (*see* Screening, OB)
 Th17 pathway, 112
 trichrome stain, 28, 29
 Orthotopic mouse lung transplant model,
 111–112
 Orthotopic rat lung transplant model, 113–114
 Orthotopic tracheal transplant model, 111
- P**
 PAMPs. *See* Pathogen-associated molecular
 patterns (PAMPs)
 Panel-reactive antibody (PRA), 138
 Pathogen-associated molecular patterns
 (PAMPs), 150
 Pattern recognition receptors (PRRs), 148
 pDCs. *See* Plasmacytoid cells (pDCs)
 Pediatric, BOS
 allograft function, 244
 description, 238
 eNO, 245
 heart-lung transplantation, 238
 incidence, 239–240
 infant lung function, 243–244
 Kaplan-Meier survival, 238–239
 management, 245–246
 risk factors (*see* Risk factors, BOS)
 transbronchial biopsy, 242–243
 PGD. *See* Primary graft dysfunction (PGD)
 Plasmacytoid cells (pDCs), 157
Pneumocystis jirovecii pneumonia, 36–38
 PRA. *See* Panel-reactive antibody (PRA)
 Primary graft dysfunction (PGD)
 and BOS, 5
 and ISHLT, 5
 lung transplantation, 5
 Prophylaxis
 antifungal, 208
 CMV, 209
 PRRs. *See* Pattern recognition receptors
 (PRRs)
Pseudomonas
 infection and colonization, 211
 lung transplantation, 206
- R**
 Rapamycin inhibitors
 everolimus, 260
 sirolimus, 259
 RAS. *See* Restrictive allograft syndrome
 (RAS)
 Regulatory T cells, 107
 Rejection. *See* Antibody-mediated rejection
 (AMR)
 Remodeling, fibrosis, 170
 Restrictive allograft syndrome (RAS)
 CLAD phenotype, 11
 classical obstructive BOS, 12
 clinical decision pathway, 53
 DAD, lung biopsy specimens, 10
 defined, 52
 description, 9
 Re-transplantation
 BOS, 305
 description, 303
 ECMO, 306
 infection, 306
 international registry, 303
 primary, 303–304
 Risk factors, BOS
 acute rejection episodes, 240
 donor age, 241–242
 GERD, 240–241
 technical factors, 240

- viral infections, 241
- Rituximab, 269–270
- Rodent heterotopic tracheal transplant model
 - costimulatory blockade, 110
 - description, 108–109
 - direct vs. indirect allorecognition, 109–110
 - IL-10, 110
 - T cell recruitment, 110–111
- S**
- Screening, OB
 - American Thoracic Society standards, 73
 - diagnosis, restriction, 74
 - FVC and FEV₁/FVC ratio, 73–74
 - post-transplant clinic visit, 73
 - six-minute walk testing, 74
- Single nucleotide polymorphisms (SNPs), 153
- SNPs. *See* Single nucleotide polymorphisms (SNPs)
- Solid organ transplantation (SOT)
 - AMR, 132–133
 - C4d staining, 134
 - HLA antibodies, 133
 - lung transplantation, 132
- SOT. *See* Solid organ transplantation (SOT)
- Spirometry
 - for airway disease, 85
 - diagnosis, BOS, 73
 - dyspnea evaluation, patients, 73
 - post-transplant clinic visits, 73
 - universal CT scoring system, 75
- Survival
 - ECP, 302
 - TLI, 300
- T**
- Tacrolimus (TAC)
 - CsA, 254
 - description, 254
- TBBx. *See* Transbronchial lung biopsy (TBBx)
- T cells
 - allogeneic, human BOS (*see* Allogeneic T cell responses, human BOS)
 - alloimmune (*see* Alloimmune T Cell responses)
 - allosensitization
 - alloantigen-self-MHC complex, 95
 - direct and indirect, 95
 - expression and class II molecules, MHC, 95–96
 - viral peptides, 96
 - regulatory, 107
 - subsets
 - CD4 vs. CD8 T cells, 96
 - polarization, 96–97
 - tregs, BOS, 107–108
- Thoracic imaging
 - BOS, LTx, 59
 - constrictive bronchiolitis, 60
 - CT (*see* Computerized tomography (CT))
 - description, 60
 - MRI (*see* Magnetic resonance imaging (MRI))
 - radiography (*see* Chest radiography)
 - Th17 pathway, 112
 - Thymoglobulin, 268
 - TLRs. *See* Toll-like receptors (TLRs)
 - Toll-like receptors (TLRs)
 - allograft rejection, 152
 - CD14 polymorphisms, 154, 155
 - CpG injection, 153
 - GVHD, 153
 - lung transplantation, 151
 - signaling, 106
 - signaling, innate immune response, 106
 - SNPs, 153–154
 - Total lymphoid irradiation (TLI)
 - Hodgkin's disease, 298
 - lung transplantation, 299
 - radiation dose, 299
 - Transbronchial lung biopsy (TBBx)
 - adequate and suboptimal, 24, 25
 - biopsy tissue sampling, ISHLT, 24
 - chronic rejection/BOS, 24
 - diagnostic yield of, 24, 26
 - intrinsic benefits and costs, 24
 - and OB
 - complications, patients, 76
 - inadequate sampling, negative biopsy, 76
 - pathologic diagnosis, 77
 - pulmonary infiltrate and clinical compromise, 77
 - suboptimal sensitivity, 76
 - surgical, 76
 - reasons, rejection, 24
 - sensitivity, 26
 - specificity, 26
- U**
- UES. *See* Upper esophageal sphincter (UES)
- Upper esophageal sphincter (UES), 222